Under the terms of the agreement, Aeterna Zentaris granted Nippon Kayaku an exclusive license to develop and market ozarelix for all potential oncological indications in Japan.
In return, Aeterna Zentaris is to receive an upfront payment upon signature, and is eligible to receive payments upon achievement of certain development and regulatory milestones, in addition to low double-digit royalties on potential net sales. Further financial details were not disclosed.
“This compound could be suitable to treat multiple forms of hormone-dependent cancer, including prostate cancer, for which promising phase II data were recently disclosed,” said Gilles Gagnon, president and CEO of Aeterna Zentaris.